Dr. Hubert S. Reyes, MD
Family Medicine (Family Medicine Physician)
2345 W Franklin St Ste 102
Evansville, IN 47712
Who else practices at this address →
Vanderburgh County is a federal mental health shortage area. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 32
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 233
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Family Medicine Physician primary
IN license 01063402A
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Deaconess Hospital Inc Evansville, IN
- Ascension St Vincent Evansville Evansville, IN
- Gibson General Hospital Princeton, IN
- The Women's Hospital Newburgh, IN
- Ascension St Vincent Warrick Boonville, IN
Medical groups
- Medihealth Primary Care LLC (3 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 233
- Services billed
- 10,217
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | 892 | 56 |
| Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | 560 | 60 |
| Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | 539 | 59 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 525 | 61 |
| Established patient office or other outpatient visit, 30-39 minutes | 408 | 188 |
| Insertion of needle into vein for collection of blood sample | 365 | 182 |
| Injection, ceftriaxone sodium, per 250 mg | 332 | 44 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 281 | 46 |
| Established patient office or other outpatient visit, 20-29 minutes | 263 | 132 |
| Injection of drug or substance under skin or into muscle | 150 | 54 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 21 companies reported 121 payments worth $2,070 in total to this clinician.
| Food and Beverage | $2,070 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 10 industry-funded studies in 2025, from 7 companies. The companies reported $287,491 in research payments for these studies, mostly to the institutions running them.
- A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with establish…
Boehringer Ingelheim Pharmaceuticals, Inc. - A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Diseas…
AstraZeneca Pharmaceuticals LP - An interventional efficacy and safety phase 3 doubleblind parallel group study to investigate intermittent prevention of menstrual migraine with rimegepant compared with placebo in women participants 18 to 45 years of…
Pfizer Inc. - A phase 3 study to evaluate the safety tolerability and immunogenicity of a respiratory syncytial virus rsv prefusion f subunit vaccine in adults 60 years of age and older
Pfizer Inc. - A Phase III Randomised Double Blind PlaceboControlled Parallel Group Study to Assess the Effect of AZD0780 on Low Density Lipoprotein Cholesterol in Patients With Elevated Low Density Lipoprotein Cholesterol and Clini…
AstraZeneca Pharmaceuticals LP - Ph IIb of Astegolimab in COPD
Genentech, Inc. - A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with establish…
Boehringer Ingelheim International GmbH - A phase 4 randomized doubleblind placebocontrolled study to evaluate the efficacy and safety of rimegepant in episodic migraine prevention with multiple dosing regimens
Pfizer Inc. - Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents
Sanofi Pasteur Inc. · Completed · NCT06128733 - A phase 1/2, randomized, observer-blinded, multi-country study to eval
GlaxoSmithKline, LLC.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.